
Wing-Kin Syn MD PhD, FEBGH, FACP, FRCPE, FRCP
Hepatology & Liver Transplantation
James F King Chair in Gastroenterology / Director, Division of Gastroenterology and Hepatology / Co-Director, Saint Louis University Liver Center / Director, Comprehensive Metabolic Clinics, SSM-SLU Hospital / Professor of Medicine / Research Track Fellowship Director / Co-Chair, SSM-St Louis Region Gastroenterology Clinical Program / Physician-Scientist / Attending Physician
Join to View Full Profile
1008 South Spring AvenueSLUCare Academic Pavilion, 2nd FloorSaint Louis, MO 63110
Phone+1 314-977-2171
Dr. Syn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Wing-Kin Syn, MD, is a gastroenterologist located in Saint Louis, MO, with subspecialties in hepatology and liver transplantation. He completed his medical education at the University of Sheffield School of Medicine in 1998. Dr. Syn serves as the Division Director and Professor of Medicine at Saint Louis University School of Medicine. Previously, he was Professor of Medicine and Attending physician at Ralph H. Johnson Veterans Affairs Medical Center and the Medical University of South Carolina. His expertise encompasses metabolic syndrome, non-alcoholic fatty liver disease, transplant hepatology, autoimmune, biliary, and genetic liver diseases. He has published > 150 papers on these topics, including options for treating metabolic dysfunction-associated liver diseases. Dr. Syn leads a basic science team that studies mechanisms of liver fibrosis and is also actively involved in clinical trials aimed at evaluating treatments for nonalcoholic steatohepatitis, autoimmune liver diseases, and liver cirrhosis.
Education & Training
- University of Sheffield School of MedicineClass of 1998
Certifications & Licensure
- MO State Medical License 2021 - 2025
- SC State Medical License 2015 - 2022
Clinical Trials
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Mar 01
- Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Start of enrollment: 2016 Oct 17
- Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Start of enrollment: 2017 Aug 30
Publications & Presentations
PubMed
- Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two target...Eda Kaya, Wing-Kin Syn, Paul Manka
Current Opinion in Gastroenterology. 2025-05-01 - 1 citationsOsteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH.Jason D Coombes, Paul P Manka, Marzena Swiderska-Syn, Danielle T Vannan, Antonio Riva
Liver International. 2025-04-01 - Low prevalence of peptic ulcer disease in hospitalized patients with cystic fibrosis: A national database study.Maya Mahmoud, Eugene Nwankwo Jr, Zidong Zhang, Neel Matiwala, Rohan Tripathi
The American Journal of the Medical Sciences. 2025-03-01
Committees
- NASH Council Member, Global Liver Institute 2018 - Present
- Committee Member, National VA NAFLD Strategic Planning Committee 2019 - 2021
- Education Steering Committee, AASLD Liver Fibrosis SIG 2018 - 2020
- Member, RHJ VAMC R&D Committee 2016 - 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: